Recent reports indicate an increasing prevalence of type 2 diabetes mellitus (TD2M) in children and adolescents around the world in all ethnicities, possibly due to increasing prevalence of obesity. Therefore, it is essential that clinicians are aware of the clinical features of T2DM in these age groups. METHODS: All published cases of T2DM in children and adolescents were evaluated and the different clinical presentations of T2DM in minorities and Caucasian described. RESULTS: Manifestation of T2DM is usually at mid-to-late puberty with few symptoms such as mild-polyuria or polydipsia. Most of the children and adolescents are extremely obese. The great majority of children and adolescents with T2DM have relatives with T2DM, and show other clinical features of the insulin resistance syndrome such as hypertension, dyslipidemia, polycystic ovarian syndrome (PCOS) or acanthosis nigricans. One-third of the minority children with T2DM and the majority of the Caucasian children with T2DM were detected by screening in the absence of symptoms. CONCLUSIONS: It is becoming increasingly clear that overweight children above the age of 10 y with (1) clinical signs of insulin resistance (acanthosis nigricans, dyslipidemia, hypertension, PCOS), or (2) relatives with T2DM, or (3) of particular ethnic populations (Asian, Indians, Africa-Americans, Hispanics), or (4) extremely obese children should be screened for T2DM. International Journal of Obesity (2005) 29, S105-S110. doi:10.1038/sj.ijo.0803065
Type 2 diabetes mellitus (T2DM) is a serious and costly disease associated with excess morbidity and mortality. It is a complex metabolic disorder of heterogeneous etiology with social, behavioral, and environmental risk factors unmasking the effects of genetic susceptibility. T2DM develops, when insulin resistance is accompanied by inadequate b-cell insulin secretion. The criteria for diagnosis of diabetes in children and adolescents are (1) symptoms of diabetes (polyuria, polydipsia, and unexplained weight loss) plus casual glucose concentration Z200 mg/dl (11.1 mmol/l) in venous plasma or capillary whole-blood samples; or (2) fasting glucose Z126 mg/dl (7.0 mmol/l) in venous or capillary plasma; or (3) 2 h glucose during oral glucose tolerance test Z200 mg/dl (11.1 mmol/l) in venous plasma or capillary whole-blood sample. 1, 2 In the absence of unequivocal hyperglycemia with acute metabolic decompensation, these criteria should be confirmed by repeat testing on a different day. 1 Recent reports indicate an increasing incidence of T2DM in children and adolescents worldwide. 1 This is particularly the case in the USA, 3 but has also been reported in other countries such as Canada, Japan, Austria, United Kingdom, and Germany 1,4-8 (see Table 1 ). This observation followed a striking increase both the prevalence and the degree of obesity in children and adolescents in many populations. 9 Overweight is at present the most common health problem facing children in both develop and developing countries. 10 Since T2DM is increasing in children and adolescents, it is essential that clinicians are aware of the clinical features of T2DM in these age groups.
Clinical presentation of T2DM in children and adolescents
Obesity is the hallmark of T2DM. Most children with T2DM are overweight or obese at diagnosis. The adverse effect of obesity on glucose metabolism is evident early in childhood. Obese children are hyperinsulinemic and have approximately 40% lower insulin-stimulated glucose metabolism compared with nonobese children. 1 Furthermore, the inverse relationship between insulin sensitivity and abdominal fat is stronger for visceral than for subcutaneous fat.
It is interesting to note that adipose tissue expanding in the obese state synthesizes and secretes metabolites and signaling proteins like adiponectin, tumor necrosis factor-alpha, leptin, and visfatin. 11, 12 These factors are known to alter insulin secretion and sensitivity and even cause insulin resistance under experimental and clinical conditions. Currently, children with T2DM are usually diagnosed over the age of 10 y and are in middle to late puberty. Puberty appears to play a major role in the development of T2DM in children. During puberty, there is increased resistance to the action of insulin, resulting in hyperinsulinemia. 13 Increased growth hormone secretion in puberty is suggested to be responsible for the insulin resistance during puberty. In the T2DM mildest form, the diagnosis is made in an asymptomatic child by screening or during a routine medical check-up by detection of glycosuria, and subsequent hyperglycemia. Usually, children with T2DM present with glucosuria without ketonuria, absent or mild polyuria and polydipsia, and little or no weight loss.
In its severest form, the child presents with evidence of severe insulin deficiency, polyuria, polydipsia, and weight loss. The minority of the children has ketonuria and/or ketoacidosis at presentation. With this clinical picture, often the distinction from type 1 diabetes mellitus (T1DM) is not possible until months later, when insulin requirements decline and a non-insulin-dependent course develops without dependence on insulin for survival.
Children with T2DM usually have a family history of T2DM. Of the patients, 74-100% have a first-or seconddegree relative with T2DM. 1, 13 Of note, diabetes in the parent or other relative may not be recognized until the child is diagnosed. The high frequency of relatives with T2DM demonstrate the strong hereditary (likely multigenic) component to the disease. 10 Acanthosis nigricans and polycystic ovarian syndrome (PCOS), disorders associated with insulin resistance and obesity, are common in youth with T2DM. Acanthosis is a cutaneous finding characterized by velvety hyperpigmented patches most prominent in the intertrigenous area and is present in up to 90% of children with T2DM in the USA. 13 It is recognized more frequently in darker-skinned obese individuals. PCOS is a reproductive disorder characterized by hyperandrogenism and chronic anovulation. Lipid disorders and hypertension also occur in children with T2DM. 13 
Clinical features of Caucasian children with T2DM
Until now, there are only few reports about Caucasian children with T2DM in Europe. [4] [5] [6] [7] [8] The clinical and metabolic presentation T2DM in Caucasian children differed from the initial reports predominantly of Afro-Americans, Hispanics or Indians. The clinical presentation of 20 European Caucasian children with T2DM is presented in Table 2 and the data concerning the metabolic presentation in Table 3 . In total, 75% of these children showed fasting blood glucose above 126 mg/dl and 65% HbA1c above the cutoff point of 6.0%. The 2-h glucose values were always above 200 mg/dl in oral glucose tolerance test. In contrast to studies on minorities in the USA with up to 25% ketoacidosis in children with T2DM, 1, 13 only one obese Caucasian adolescent has been published with ketoacidosis at manifestation. 4 Most of the European Caucasian children and adolescents with T2DM were asymptomatically at diagnosis (see Table 4 ). The minority populations demonstrated at manifestation of diabetes frequently more symptoms and higher insulin and C-peptide levels, pointing to greater insulin resistance. 13 African-American children are more insulin resistant than Caucasian children. 14 According Clinical presentation of TD2M T Reinehr to this, acanthosis nigricans, a clinical sign of insulin resistance, occurred more frequently in these populations.
Another explanation for these differences may be the fact that most of the Caucasian children with T2DM were detected by screening, in contrast to many of the nonCaucasian children published, who had presented with overt clinical symptoms. 13 The non-Caucasian obese children with T2DM detected by screening in the US had similar levels of insulin and insulin resistance index like Caucasian children with T2DM. 15 
Differential diagnosis of T2DM in children and adolescents
Individuals with T2DM may have clinical presentations indistinguishable from those of patients with other types of diabetes. This is relevant because as the number of children with T2DM increases it becomes increasingly important to classify their diabetes correctly so that appropriate therapy may be instituted. Typically, children with T1DM are not overweight and have recent weight loss, polyuria, and poydipsia (see Table 5 ). They usually have a short duration of symptoms and frequently have ketosis; 30% have ketoacidosis at presentation. 1 After metabolic stabilization, they may have an initial period of diminished insulin requirement, after which they require insulin for survival. Of children with T1DM, 5% have a first-or second-degree relative with the same disease. Children with idiopathic T1DM may be difficult to distinguish from those with T2DM. The majority of those described with idiopathic T1DM have what has been termed atypical diabetes mellitus and are African American.
1 Their family history is positive for early-onset diabetes in many relatives in multiple generations. Insulin may not be required for survival after the resolution of the acute metabolic deterioration. Maturity-onset of diabetes of the young (MODY) is another rare form of diabetes in children, which includes several disorders caused by monogenic defects in b-cell function. 16 MODY 2 (defect in glucokinase) and MODY 3 (defect in hepatocyte nuclear factor (HNF) 1a) are the most frequent types of MODY. Patients with MODY have a dominant genetic trait, usually are nonobese and have low fasting insulin levels. Recent studies suggest that the clinical presentation of MODY is broad, ranging from asymptomatic hyperglycemia to a severe acute presentation. MODY has been reported in all races/ethnicities. In most patients with diabetes, classification can be made reliably on the basis of clinical presentation and course. 1 In the unusual circumstance that requires a specific classification to be made, other test may be necessary, such as fasting insulin or C-peptide determination and, occasionally, b-cell autoantibodies measurements (see Figure 1) . Individuals with T2DM usually do not have autoantibodies to b-cell proteins; fasting insulin and C-peptide levels Clinical presentation of TD2M T Reinehr are elevated, although not as elevated as might be excepted for the degree of hyperglycemia. Specific autoantibodies to insulin, to GAD-II, or to tyrosine phosphatases insulin antibodies (IA)-2 and IA-2b are found at presentation in 85-98% of individuals with immune-mediated T1DM. 1 Endogenous fasting insulin and C-peptide is low in T2DM, with little or no increase after oral or intravenous glucose administration.
Complications of T2DM in children and adolescents
The chronic complications of diabetes in adults include macrovascular disease like accelerated development of cardiovascular disease leading to stroke and myocardial infarction, and microvascular diseases like retinopathy, nephropathy and neuropathy leading to end-stage renal disease, loss of visual acuity, and limb amputations. All of these complications contribute to the excess morbidity and mortality in individuals with diabetes.
They are only few data concerning complications of T2DM in childhood. Assessing trial data from adults and extrapolating to outcomes in children is fraught with difficulties. One notable outcome of the UKPDS analysis was the observation that the accrual of end points was a timedependent process. 17 Such observations have particular implications for the onset of diabetes already in childhood. The UKPDS observational analysis showed clear logarithmic association of risk with increasing glycemia. It is very likely that these relative risks apply to children, and the conclusion must therefore be that diagnosis and aggressive control of glycemia is a mandatory requirement if we are to reduce the burden of end points.
We know little about the onset and progress of marcovascualar disease in children with T2DM. Arteriosclerosis is a time-dependent phenomenon, and thus the absolute time from diagnosis to developing pathological cardiovascular lesions may be many yearsFin that sense these children may be protected by age since they do not have pre-existing age-related cardiovascular disease. However, it is almost certain that they will develop an excess cardiovascular morbidity early in life.
Microvascular disease is the hallmark of hyperglycemia diagnosed at a young age. Data from Japanese and Pima Indian children show the presence of microvascular diabetic complications already at diagnosis and follow-up. 1, 13 In Japanese children, incipient retinopathy was detected in 36% of the cases at the time of diagnosis, and in 39% of the cases at 2 y follow-up. Therefore, dilated eye examinations should be performed in children with T2DM. Among Pima Indian children, 22% had microalbuminuria, and at followup between 20 and 29 y of age 60% had microalbuminuria and 17% had already macroalbuminuria. 1 In conclusion, screening for microalbuminuria should be performed yearly in children with T2DM. It is unclear whether foot examinations are important in children. Other than testing for and treating elevated blood pressure and lipid abnormalities studies to detect macrovascular disease are probably not indicated, although there are no data in this age group. Consistent with the recommendations for screening in adults, only children at substantial risk for the presence or the development of T2DM should be tested. Acknowledging the clinical presentation of T2DM and that there are insufficient data to make definite recommendations, testing seems meaningful in overweight children and adolescents at the onset of puberty in high-risk patients who (1) display a family history of T2DM in first-and second-degree relatives or (2) signs of insulin resistance (acanthosis nigricans) or (3) conditions associated with insulin resistance (hypertension, dyslipidemia, polycystic ovary syndrome) or (4) belong to a particular ethnic groups (Indians, African-Americans, Hispanics, Asians) and (5) in extremely obese children. 1, 18 Testing should be performed every 2 y starting at the age of 10 y or at onset of puberty if it occurs in a younger age. 1, 18 HbA1c is not a useful screening tool, since one-third of the asymptomatic children with T2DM demonstrated normal values. 18 Since fasting blood glucose failed to diagnose diabetes in one-quarter of children with T2DM in the European cohort, the oral glucose tolerance test seems to be a better screening tool even if fasting glucose is preferred because of its lower costs and greater convenience. 18 
Treatment of T2DM in children and adolescents
The ideal goal of treatment is normalization of blood glucose values and HbA1c. Successful control of the associated comorbidities, such as hypertension and dyslipidemia, is also important. The ultimate goal of treatment is to decrease the risk of acute and chronic complications associated with diabetes. Most of the recommended guidelines for treatment in children with T2DM are extrapolated from experience gained in adults. Despite of severe manifestation, initial management of obese children and adolescents with T2DM should consist of medical nutrition therapy with behavior modification strategies for lifestyle change aiming at increasing physical activity and decreasing weight. Outpatient long-term obesity intervention programs for the children and their parents based on behavioral components, physical exercise, and nutrition education (eg low-fat diet, decreased consumption of sugar drinks) including individual psychological care of the child and his or her family should be performed. Daily activity levels of the children should be increased (for instance, use of bicycles instead of bus to go to school, and decreasing television viewing). An improvement of the insulin resistance is to be suspected at a significant increase in physical activity 20 or at a reduction of BMI of 2, which means a stable weight over 1 y in growing children. 21 Accordingly, a reduction of BMI of 2 is sufficient to treat T2DM in children and adolescents. 22 Since only a few of youths with T2DM can be treated with diet and exercise alone, 1,5 pharmacological intervention is frequently required to achieve normoglycemic state. Metformin, a biguanide, is undoubtedly the most appropriate starting point for pharmacological treatment in children with TD2M. Metformin decreases hepatic glucose output and enhances primarily hepatic and also muscle insulin sensitivity without a direct effect on b-cell function. Metformin has the advantage of weight reduction and decrease in lipids without the risk of hypoglycemia. If monotherapy with metformin is not successful over a reasonable period of time (3-6 months), several alternatives can be considered: some clinicians would add a sulfonylurea, which promote insulin secretion. Other insulin secretogogues (like meglitinide analogs) and promoters of insulin sensitivity (like thiazolidinediones) are acceptable as well as glucosidase inhibitor, but these have been less frequently used in children. Clinical features suggesting treatment with insulin include failure of oral antidiabetic drugs or manifestation with dehydratation, presence of ketosis, and acidosis.
Conclusions
T2DM is rare in childhood and adolescence, but recent reports indicate an increasing prevalence around the world in all ethnicities, possibly due to increasing prevalence of obesity in children and adolescents. It is essential that clinicians are aware of T2DM also in European Caucasian youths as well as those from high-risk populations since T2DM frequently manifests at the onset of the disease without symptoms. It is becoming increasingly clear that overweight children above the age of 10 y with (1) clinical signs of insulin resistance (acanthosis nigricans, dyslipidemia, hypertension, PCOS), or (2) relatives with T2DM, or (3) of particular ethnic populations (Asian, Indians, AfricaAmericans, Hispanics), or (4) extremely obese children should be screened for T2DM. New research is needed into current national prevalence rates and subsequently, effective methods of prevention and management.
